GlobeNewswire

“Under the Radar” Industry Group Fighting BEC Phishing Receives 2018 M3AAWG JD Falk Award

Del

NEW YORK, Oct. 10, 2018 (GLOBE NEWSWIRE) -- A private, sequestered email group that you probably have never heard of – but that has helped prevent millions of dollars in fraud and assisted in taking down thousands of Nigerian scheme email accounts – was honored today with the 2018 JD Falk Award from the Messaging, Malware and Mobile Anti-Abuse Working Group.  The BEC List founder and administrator, Ronnie Tokazowski, and the private email group of more than 530 members received the annual award, which recognizes an innovative project that protects online users, at the M3AAWG 44th General Meeting in Brooklyn.

The Business Email Compromise List deals with a broad assortment of criminal activity and deceptive emails, often described as “Nigerian” schemes, that use phishing and fake social media activities to attract victims. By sharing information and expertise, they have blocked spoofed emails and malware; tracked real estate, romance, IRS, W2 and lottery schemes; and identified the money “mules” used to transfer illicit funds. BEC fraud accounts for more than $12 billion in losses globally and threatens users in 150 countries, according to the FBI’s IC3 (Internet Crime Complaint Center).

The private list is managed by Tokazowski, senior malware analyst at Flashpoint, and includes cybersecurity professionals from Fortune 500 companies, leading threat research organizations, anti-virus firms, and internet infrastructure companies, many of them competitors. Law enforcement participants include the U.S. Federal Bureau of Investigation, the U.S. Internal Revenue Service Online Fraud Detection and Prevention group, the U.S. Secret Service, and other entities. While many members chose to remain anonymous, a partial list of participating organizations is available at www.m3aawg.org/FalkAwardOrgs2018. A video describing what the group has learned about compromised email and the list’s accomplishments is at https://youtu.be/Ues_oRsTBNc.  

The award also recognizes the impact a single individual can have on fighting abuse. The private group was Tokazowski’s idea and he has served as the list administrator since its inception three years ago.  Since then, dozens of organizations have cooperated on the list to protect end-users and fight fraud.

“From the start, Ronnie has diligently managed the BEC List as a trusted environment, always emphasizing the need for confidentiality and respect for members’ opinions. As a result, it has become an important anti-abuse channel where actionable information is shared throughout the day between hundreds of people. This cooperative sharing has greatly benefited end-users, even though they are not aware of its existence, as the list’s behind-the-scenes involvement has contributed to over a hundred fraud-related arrests,” said Severin Walker, M3AAWG Chairman of the Board.

In 2015, Tokazowski initially reached out to a few cybersecurity researchers and law enforcement agents to discuss the compromised emails he was seeing in his work and the list was created that December with about a hundred participants. They originally focused on conventional BEC phishing emails that impersonate a targeted CEO requesting that the company’s financial staff wire funds to a fraudulent account. But as the group studied the problem, they realized it was much more extensive and often involved malware and various online and social media ruses.

Nigerian Rappers Praise Scams

Tokazowski said, “It takes a diverse set of perspectives and expertise to address business compromise email and it’s not something researchers, law enforcement, and especially the targeted users can tackle on their own. I like to describe it as, ‘it’s not my problem, it’s not your problem, it’s a problem for everyone in the industry.’  We have to come together to fix it and understand how it works.”

This effort includes learning how the perpetuators think, according to Tokazowski. “We’re also looking to identify the criminals’ motivation and how this affects the schemes. There is a different culture in many of the countries where these crimes originate, and the deception is often justified in these regions because it’s one of the few ways to earn money. You have popular rappers in Nigeria praising the scammers efforts and their methods to ‘wire wire’ stolen money from a BEC target, but without ever acknowledging the victim’s pain,” he said.

The M3AAWG JD Falk Award is presented annually to recognize a project that helps protect the internet and embodies a spirit of volunteerism and community building. The 2018 award was presented during the M3AAWG 44th General Meeting that opened October 8 in Brooklyn, New York. Over 500 security experts, ISPs, researchers, public policy representatives and vendors are participating in the four-day meeting that features more than 50 cybersecurity and information sharing sessions. M3AAWG holds three meetings each year, including one in Europe, to develop best practices and other work that will protect online users. The next M3AAWG meeting will be February 18-21, 2019 in San Francisco. 

About the Messaging, Malware and Mobile Anti-Abuse Working Group (M 3 AAWG)

The Messaging, Malware and Mobile Anti-Abuse Working Group (M3AAWG) is where the industry comes together to work against bots, malware, spam, viruses, denial-of-service attacks and other online exploitation. M3AAWG (www.m3aawg.org) members represent more than one billion mailboxes from some of the largest network operators worldwide. It leverages the depth and experience of its global membership to tackle abuse on existing networks and new emerging services through technology, collaboration and public policy. It also works to educate global policy makers on the technical and operational issues related to online abuse and messaging. Headquartered in San Francisco, Calif., M3AAWG is driven by market needs and supported by major network operators and messaging providers.

Media Contact: Linda Marcus, APR, LMarcus@astra.cc, Astra Communications, mobile: +1-949-887-8887

M3AAWG Board of Directors and Sponsors: Adobe Systems Inc.; AT&T; Comcast; Endurance International Group; Facebook; Google, Inc.; LinkedIn; Mailchimp; Marketo, Inc.; Microsoft Corp.; Oath (Yahoo/AOL); Orange; Proofpoint; Rackspace; Return Path, Inc.; SendGrid, Inc.; Vade Secure; and VeriSign, Inc.

M3AAWG Full Members: 1&1 Internet SE; Agora, Inc.; Akamai Technologies; Campaign Monitor; Cisco Systems, Inc.; CloudFlare, Inc.; Cyren; dotmailer; eDataSource Inc; ExactTarget, Inc.; IBM, iContact; Internet Initiative Japan (IIJ); Liberty Global; Listrak; Litmus; McAfee; Mimecast; Oracle Marketing Cloud; OVH; PayPal; Spamhaus; SparkPost; Splio; Symantec; USAA; and Valimail.

A complete member list is available at http://www.m3aawg.org/about/roster.    

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®16.6.2019 18:00:00 CESTPressemelding

CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will host a conference call and webcast tomorrow morning, June 17, 2019, at 8:00 AM ET. Management looks forward to reviewing top-line data from PROTECT, one of two pivotal Phase 3 studies for Sci-B-Vac®, the company’s trivalent hepatitis B vaccine. Conference Call and Webcast Details The live webcast and slide presentation can be accessed via the Events/Presentations page in the investors section of the company’s website, https://www.vbivaccines.com/investors/events-presentations/, or by clicking this link: https://edge.media-server.com/m6/p/7ryhzgu2. A replay of the webcast will be archived on the company’s website for 90 days following the live conference call. To listen to the live conference call, please dial: - Toll-free U.S. & Canada Dial-In: (866) 602-1050 - Internat

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad